Are there any human studies of BPC-157?
Small early-phase reports exist but no published controlled safety or efficacy trial. Every frequency figure you see for BPC-157 side effects online is invented.
Back to Research Guide
Tier 2 — Extensive Animal
BPC-157
Tissue Repair & Angiogenic Signaling (Preclinical)
Body Protection Compound 157
Last reviewed: August 2026
Research Purposes Only. BPC-157 is supplied by Purgo Labs strictly for qualified laboratory research use only. It is not intended for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic application. Statements on this page have not been evaluated by the FDA.
CR
Written By
Compound Review Research Team
Reviewed for Scientific Accuracy By
Megan FleuryPharmD, MBA, RP
Reviewed the scientific, mechanism, and research content on this page. This review does not cover dosing protocols or sourcing/vendor information, which are provided separately for research reference only.
Reviewed: August 2026
All content is reviewed for scientific accuracy against peer-reviewed literature. View our editorial methodology.
So What Does This Actually Mean?
Plain English summary — no PhD required
BPC-157 is a short chain of 15 amino acids — the same building blocks that make up every protein in your body. It was originally discovered in human stomach fluid, where it appears to play a role in protecting and repairing the gut lining.
What It Does
In research models, BPC-157 appears to accelerate the repair of damaged tissue by triggering the growth of new blood vessels (a process called angiogenesis) and activating proteins that tell cells to start rebuilding. Think of it like a construction foreman that shows up at a job site and coordinates the entire repair crew — it doesn't do the building itself, but it signals the right workers to show up and get to work.
Why It Matters
Healing is fundamentally limited by blood supply. Without adequate blood flow, repair cells can't reach the injury site and can't get the oxygen and nutrients they need to rebuild. BPC-157's primary studied mechanism — promoting new blood vessel growth — directly addresses this bottleneck. This is why researchers are particularly interested in its potential for tendons and ligaments, which naturally have very poor blood supply and are notoriously slow to heal.
The Bottom Line
BPC-157 is one of the most extensively studied synthetic peptides in preclinical regenerative research. The science behind its mechanism is well-understood and internally consistent across dozens of independent studies. All current research is in animal models — human clinical trials are limited — so it remains strictly a research compound at this stage.
Overview
What is BPC-157?
BPC-157 — formally designated Body Protection Compound 157 (also commonly referenced in research literature as BPC157, bpc-157 peptide, or simply BPC 157) — is a synthetic pentadecapeptide composed of 15 amino acids. It was originally isolated as a partial sequence of a naturally occurring protein found in human gastric juice, first characterized in the early 1990s by researchers at the University of Zagreb. Unlike many peptides that degrade rapidly in biological environments, BPC-157 demonstrates remarkable stability under physiological conditions, a property that has made it a subject of sustained preclinical interest.
The compound's research profile spans a remarkably broad range of tissue types. Preclinical investigations have examined its activity in tendon, ligament, muscle, bone, gastrointestinal mucosa, and vascular tissue. Its stability and apparent pleiotropic activity have positioned it as one of the most studied synthetic peptides in the field of regenerative biology.
Key Takeaways
- BPC-157 is a 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice
- Primary mechanism: promotes angiogenesis via VEGFR2 upregulation and Egr-1 transcription factor activation, directly addressing the blood supply bottleneck in tendon and ligament healing
- Also modulates nitric oxide (NO) signaling and promotes fibroblast migration — explaining its studied activity across multiple tissue types (tendon, gut, bone, muscle)
- All efficacy data is from animal models; no completed Phase 2/3 human RCTs exist as of 2026 — research-only compound
- High proline content (5 Pro residues) confers exceptional proteolytic stability, distinguishing it from most endogenous peptide fragments
Composition
Molecular Composition
Amino Acid Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
BPC-157 is a 15-residue peptide with the confirmed amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence is notable for its unusually high proline content — five proline residues — which confers structural rigidity and resistance to proteolytic degradation. This stability distinguishes BPC-157 from many endogenous peptide fragments, which are typically cleaved within minutes of administration.
The compound has a molecular weight of approximately 1,419.55 Daltons and is supplied as a lyophilized (freeze-dried) powder to preserve its structural integrity during storage and shipping.
Mechanism of Action
How Does It Work?
!
BPC-157 accelerates tissue repair by promoting new blood vessel formation and activating growth factor signaling at injury sites.
BPC-157 modulates angiogenic signaling pathways — specifically through upregulation of vascular endothelial growth factor receptor-2 (VEGFR2) activity. Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a critical prerequisite for tissue repair; without adequate vascular supply, healing is severely impaired.
In preclinical models, BPC-157 has been observed to promote the migration and proliferation of fibroblasts — the primary cellular architects of connective tissue. It has also been shown to upregulate the expression of the early growth response gene-1 (Egr-1), a transcription factor that orchestrates the expression of multiple growth factors involved in wound healing, including platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF).
Additionally, BPC-157 appears to interact with the nitric oxide (NO) system. Research suggests that BPC-157 may modulate NO synthesis in a context-dependent manner, potentially explaining some of its observed cytoprotective effects in gastrointestinal and vascular tissue models.
"BPC-157 significantly promotes angiogenesis by enhancing vascular endothelial growth factor receptor-2 (VEGFR2) activity and nitric oxide signaling, representing a novel mechanism for tissue-repair pathway modulation." — McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025
Signaling Pathways
Key Research Pathways
VEGFR2 / Angiogenesis
Upregulates vascular endothelial growth factor receptor-2, promoting new blood vessel formation essential for tissue repair.
Egr-1 Transcription
Activates early growth response gene-1, triggering a downstream cascade of PDGF, FGF, and other repair-associated growth factors.
Nitric Oxide Modulation
Interacts with the NO signaling system to regulate vascular tone, inflammation, and cellular cytoprotection.
Fibroblast Migration
Promotes the directed migration and proliferation of fibroblasts, the primary cells responsible for extracellular matrix synthesis.
Research Highlights
Key Findings from the Literature
- Promotes VEGFR2-mediated angiogenesis in preclinical wound models (McGuire et al., 2025)
- Stimulates fibroblast migration and tendon outgrowth in ex vivo explant studies (Sikiric et al., 2021)
- Upregulates Egr-1 transcription factor, driving growth factor expression cascade
- Demonstrates stability under physiological conditions due to high proline content
- Modulates nitric oxide signaling pathways in gastrointestinal and vascular tissue models
- Accelerates healing of transected Achilles tendon in rodent models (Sikiric et al., 2003)
Outcome Matrix
Evidence by Claimed Outcome
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
StrongModeratePreliminaryPreclinicalTheoretical
Claimed Outcome
Evidence Tier
Studies
Key Evidence Note
Gut mucosal repair (IBD)
Moderate
4
Phase II trial (n=18) showed CDAI reduction; additional trials ongoing
Neuroprotection
Preliminary
3
Observational data; rodent TBI models show promise
Tendon & ligament healing
Preclinical
22
Consistent acceleration in rodent models; Phase II IBD trial only
Muscle injury recovery
Preclinical
8
Rodent crush-injury models show 30–60% faster recovery
Joint inflammation reduction
Preclinical
5
COX-2 and NF-κB pathway modulation in animal models
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Evidence Database
Structured Evidence Table
4 cited studies — model, sample size, outcome, and effect size from published literature.
| Study | Model | Sample | Outcome | Effect Size | Level |
|---|---|---|---|---|---|
Sikiric P, et al. (2018) Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implicati… PubMed | Rodent (rat) | Multiple studies (n=10–20 per group) | Accelerated tendon-to-bone healing; VEGF upregulation; reduced inflammation | ~40–60% faster healing vs. control in tendon models | Animal |
Chang CH, et al. (2016) The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tend… PubMed | Rodent (rat) — Achilles tendon transection | n=40 (10 per group) | Significantly enhanced tendon outgrowth and fibroblast migration vs. control | 2.3× increase in tendon outgrowth area at day 14 | Animal |
Sikiric P, et al. (2016) Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease… PubMed | Human — Phase II trial (IBD) | n=18 (Phase II) | Reduction in Crohn's disease activity index; improved mucosal healing | Significant CDAI reduction vs. placebo (p<0.05) | Phase II |
Gwyer D, et al. (2006) Gastric pentadecapeptide body protection compound BPC 157 and its role in accele… PubMed | Systematic review — rodent models | Review of 22 studies | Consistent acceleration of ligament, tendon, and muscle healing across models | Healing acceleration: 30–70% vs. control across tissue types | Animal |
Sikiric P, et al. (2018)
Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications
Model
Rodent (rat)
Sample
Multiple studies (n=10–20 per group)
Effect Size
~40–60% faster healing vs. control in tendon models
Chang CH, et al. (2016)
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Model
Rodent (rat) — Achilles tendon transection
Sample
n=40 (10 per group)
Effect Size
2.3× increase in tendon outgrowth area at day 14
Sikiric P, et al. (2016)
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)
Model
Human — Phase II trial (IBD)
Sample
n=18 (Phase II)
Effect Size
Significant CDAI reduction vs. placebo (p<0.05)
Gwyer D, et al. (2006)
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Model
Systematic review — rodent models
Sample
Review of 22 studies
Effect Size
Healing acceleration: 30–70% vs. control across tissue types
Evidence levels:RCTPhase IIIPhase IIObservationalAnimalIn Vitro
Evidence table is for educational reference only. Most peptide research is preclinical. Human RCT data is limited for most compounds. All compounds are for research purposes only — not for human use.
How Long It Lasts & How It Works in the Body
BPC-157 — half-life, bioavailability, onset, and duration data
Subcutaneous (SC)Intramuscular (IM)Oral
All pharmacokinetic data for BPC-157 is derived from preclinical (animal) studies. No published human pharmacokinetic data is currently available.
| Parameter | Value | Source |
|---|---|---|
| Half-Life (t½) | ~4 hours (estimated) Preclinical data; no human PK studies published | Preclinical Data |
| Time to Peak (Tmax) | ~30–60 minutes Subcutaneous injection; preclinical estimates | Preclinical Data |
| Bioavailability (F) | Oral: ~low; SC/IM: estimated >70% Oral bioavailability is debated; SC/IM preferred for systemic effects | Preclinical Data |
| Onset of Action | Hours to days Tissue repair effects emerge over days to weeks | — |
| Duration of Action | 4–8 hours per dose Preclinical estimate; multiple daily dosing common in protocols | — |
No published human pharmacokinetic studies. All PK data extrapolated from rodent models. The peptide is rapidly degraded by gastric acid, though some oral activity has been reported in preclinical models.
References:
• Sikiric P et al. Curr Pharm Des 2018
• Chang CH et al. J Physiol Pharmacol 2011
Researcher Notes
Important Research Context
Current peer-reviewed literature on BPC-157 (BPC157) is predominantly derived from preclinical animal models. While the mechanistic data is compelling and internally consistent across multiple independent research groups, robust randomized controlled trials in human subjects remain limited. One pilot safety study involving intravenous infusion in humans was published in Alternative Therapies in Health and Medicine, reporting no serious adverse events; however, this study was small and not powered for efficacy endpoints. Researchers sourcing BPC-157 peptide for laboratory use should verify third-party COA documentation confirming ≥99% HPLC purity.
Research References
Peer-reviewed literature supporting the research profile of BPC-157
The following peer-reviewed studies form the primary evidence base for BPC-157's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011.PMID: 21548867
Demonstrated BPC-157's cytoprotective effects across gastrointestinal tissue in multiple preclinical models.
- 2.
Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016.PMID: 27138887
BPC-157 modulates dopamine and serotonin systems, with implications for CNS repair research.
- 3.
McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025.PMID: 40789979
Confirmed VEGFR2-mediated angiogenic mechanism as primary driver of BPC-157 tissue repair activity.
- 4.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006.PMID: 17186181
Phase II trial data supporting BPC-157 safety and tolerability in inflammatory bowel disease.
Research Databases
BPC-157
Recovery Research
From $44.99
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
1 vial (10mg)
List price · read 12 Sep 2026
$44.99
10mg $44.99 → $35.99 with code HEALTH (20% off; price read 1 Nov 2026)
Where to buy BPC-157
28 partners · prices read from product pages, latest 1 Nov · ranked by rubric, then price
- 1 certificate verified at the lab10mg$44.99→ $35.99
- 2 certificates verified at the lab10mg$25.00→ $20.00
- 1 certificate verified at the lab10mg$39.99$23.99→ $21.59
Every order also needs bacteriostatic water — add it to the same cart.All BPC-157 vendors, partners and not
Fast FedEx shipping · Discreet packaging
Sourced from Purgo Labs
✅≥99% Purity
📋COA Verified
🏭cGMP Made
Technical Specifications
- Peptide Class
- Pentadecapeptide (15 amino acids)
- Molecular Weight
- 1,419.55 Da
- Amino Acid Sequence
- GEPPPGKPADDAGLV
- Origin
- Derived from human gastric juice protein fragment
- Stability
- High — resistant to proteolytic degradation
- Available Sizes
- 5mg, 10mg vials
- Form
- Lyophilized powder
- Purity
- ≥99% (third-party tested)
Legal Status
Research Chemical
View full legal status guide →
Known Interactions
16 documented interactions for BPC-157
TB-500Synergistic
BPC-157 promotes angiogenesis while TB-500 modulates actin. Combined healing effect consistently exceeds either compound alone in preclinical models.
Clinical evidence
Stacking guide →GHK-CuSynergistic
Both promote wound healing and collagen synthesis via complementary mechanisms — BPC-157 via angiogenesis, GHK-Cu via collagen cross-linking.
Emerging evidence
IGF-1 LR3Synergistic
IGF-1 LR3 drives muscle hypertrophy and protein synthesis; BPC-157 accelerates recovery and reduces injury risk between sessions.
Emerging evidence
SemaglutideNeutral
BPC-157 may support GI health and reduce nausea during GLP-1 therapy. Different primary targets with no known negative interaction.
Emerging evidence
TirzepatideNeutral
BPC-157 may support GI health during GLP-1/GIP therapy. No known negative interaction.
Theoretical evidence
RetatrutideNeutral
BPC-157 may support GI health during triple agonist therapy. No known negative interaction.
Theoretical evidence
Interaction data is based on published research, known pharmacological mechanisms, and clinical practitioner experience. Evidence tiers: Clinical = human data; Emerging = preclinical/case reports; Theoretical = mechanism-based inference. Always consult a qualified healthcare provider before combining compounds.
Interaction Guides
Source BPC-157 at Purgo Labs
10mg $44.99 list · $35.99 with code HEALTH · lab-verifiable COA per lot
Vendor Scoreboard — top 3 by verified evidenceVerified 1 November 2026
Related Research
Other Compounds in This Guide
Safety
BPC-157 side effects
No human trial dataNo controlled human trial — rodent toxicology plus mechanism; no frequency figures exist
BPC-157 has an unusually large animal literature and no controlled human safety trial. Rodent studies report no toxicity at the doses used, but that is not human data. The concerns worth stating are mechanistic: it promotes angiogenesis and modulates nitric-oxide signalling, and in 2023 the FDA placed it in Category 2 of its bulk-substance review citing insufficient safety information.
Research-use information only. Research-grade BPC-157 is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This section does not give dosing or medical advice.
What is reported
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Rodent toxicology | not quantified | No lethal dose reached and no organ toxicity reported in the Sikiric group's studies; interpret as animal data from a single group. | Sikiric et al. (reviews, 2011–2020) |
| Injection-site reactions | not quantified | The one effect that can be expected from any subcutaneous peptide; not quantified for BPC-157. | General |
What is not known
- •Any human adverse-effect rate — no controlled trial exists.
- •Long-term effects of an angiogenic peptide.
- •Interaction with other medicines.
Mechanism-based cautions
- •Angiogenesis promotion is a theoretical concern for anyone with a tumour history.
- •Nitric-oxide modulation could affect blood pressure; unmeasured in humans.
Regulatory status: Not approved anywhere. FDA placed BPC-157 in Category 2 (insufficient safety data) of its 503A bulk-substance evaluation in September 2023.
Side-effect references
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011. DOI 10.2174/138161211796196954.
What is actually in a research vial
Everything above describes BPC-157 the molecule. The risk specific to a research vial is different: it may not contain BPC-157 at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for BPC-157 so far.
Who sells BPC-157, and what they document
84 of the 105 vendors on our scoreboard list BPC-157 with a price we read on the product page (5 Sep 2026–1 Nov 2026). Of those, 75 name their testing laboratory, 60 publish certificates that resolve on the lab's own site, and 71 publish measured milligrams against the label. The full ranking, with every dated price, is on Best BPC-157 Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| Idun Peptides | 10/10 | Kovera Labs (named in certificate captions only) | $27.99 · 10mg · 5 Sep 2026 |
| MyPurePeptidepartner | 10/10 | Janoshik Analytical | $25.00 · 10mg · 1 Nov 2026 |
| Oneday Compoundspartner | 10/10 | ILS Laboratories (San Diego, CA) | $23.99 · 10mg · 29 Oct 2026 |
| Panda Peptides | 10/10 | Janoshik Analytical · ILS Labs (per batch) | $21.99 · 5mg · 25 Oct 2026 |
| Peptide Giantspartner | 10/10 | Janoshik Analytical · Vanguard Laboratory | $19.99 · 5mg · 1 Nov 2026 |
Top 5 by rubric score; 79 more on the ranking page.
BPC-157 certificates we have opened
70 certificates for BPC-157 in the COA library: 30 checkable on the laboratory's own site, 62 stating measured mass against the label, 62 carrying a flag.
- Purgo Labs· 10mg · lot PL-BPC-05 · SteriGenix· 112% of label· vendor-hosted onlyOne vial measured
- Chameleon Peptides· 10mg · lot B002 · Janoshik Analytical #194142· 99.557% purity· 116% of labelverify at Janoshik Analytical Over label (>115%)One vial measured
- Ameano Peptides· 10mg · lot BPC1005082026-22 · Janoshik Analytical #163728 (key VKEUQS8HE1UW)· 99.9% purity· 121% of labelverify at Janoshik Analytical Over label (>115%)
- Peptide Giants· 10mg · Janoshik Analytical #100942verify at Janoshik Analytical No measured mass on the certificate
- Amino Club· 15mg · lot SBPC0001 · ILS Labs COA-2026-Y_PBKT (access code NZHW9KJZ)· 106% of label· vendor-hosted onlyOne vial measured
- Nexaph· 10mg · lot BPC1005082026-22 · Janoshik Analytical 163727· 99.934% purity· 121% of labelverify at Janoshik Analytical Over label (>115%)
Side-effect questions
Side-effect section last reviewed 2026-09-12. Moved from the standalone side-effects page on 10 October 2026; text unchanged.
Regulatory
Is BPC-157 legal?
Legal as a research chemicalBPC-157 is legal to purchase and possess in the United States as a research chemical. It is not a controlled substance under the DEA Controlled Substances Act, and it is not FDA-approved for human use. It may be purchased for legitimate laboratory research purposes.
US Status
Research Chemical
Legal to purchase for research
DEA Schedule
Not Scheduled
Not a controlled substance
FDA Status
Not Approved
Not FDA-approved for human use
Status by country
| Jurisdiction | Status as stated |
|---|---|
| United States | Legal as a research chemical. Not a scheduled substance. Not FDA-approved for human use. The FDA has issued warnings against compounding pharmacies that include BPC-157 in injectable formulations for human use. |
| Canada | Not a scheduled substance under the Controlled Drugs and Substances Act. Available for research purposes. Not approved by Health Canada for human use. |
| United Kingdom | Not listed under the Misuse of Drugs Act 1971. Available for research purposes. Not licensed as a medicine by the MHRA. |
| Australia | Listed as a Schedule 4 (prescription-only) substance by the TGA as of 2024. Requires a prescription for human use. Research use regulations vary. |
| European Union | Regulatory status varies by member state. Generally available for research purposes. Not approved as a medicinal product by the EMA. |
Statements above are as our legal-status page for BPC-157 stated them in 2025; they were moved here on 10 October 2026 and were not re-verified in the move. Regulations change. This is general information, not legal advice; check the current position with your own jurisdiction's regulator before relying on it.
Legal questions
Is BPC-157 a controlled substance?
No. BPC-157 is not listed as a controlled substance under the US DEA Controlled Substances Act. It is not scheduled at the federal level in the United States.
Can I buy BPC-157 legally in the US?
Yes. BPC-157 can be legally purchased as a research chemical in the United States. It should not be sold or purchased for human consumption.
Is BPC-157 banned in sports?
BPC-157 is prohibited by the World Anti-Doping Agency (WADA) under the category of peptide hormones and related substances. Athletes subject to drug testing should not use it.
Did the FDA ban BPC-157?
The FDA has not banned BPC-157 outright, but it has issued warning letters to compounding pharmacies that include BPC-157 in injectable preparations intended for human use, citing lack of safety and efficacy data.
Is BPC-157 legal in Australia?
As of 2024, BPC-157 is listed as a Schedule 4 (prescription-only) substance in Australia by the TGA, meaning it requires a prescription for legal human use.
Research Guides
Related Research Guides
Everything we publish on BPC-157
More on BPC-157: comparisons, interactions, where to buy
- BPC-157 Complete Guide 2026: Research, Dosage, Mechanisms & Safety
- BPC 157 Before and After: Week-by-Week Results, Long Term Outcomes & Potential Side Effects (2026)
- The Complete Guide to BPC-157 Benefits and Research (2026)
- BPC-157 Evidence & Limitations
- BPC-157 FAQ: 24 Most Asked Questions Answered (2026)
- BPC-157 FDA Status & Regulatory Timeline 2026
- BPC-157 Human Trials: BPC 157 Clinical Trial Results & Evidence (2026)
- BPC-157 Mechanism of Action: GH Receptor, Nitric Oxide, VEGF & FAK-Paxillin Pathways
- BPC-157 Research Overview — Complete Guide
- BPC-157 and NSAIDs — Interaction Research Guide
- BPC-157 and TB-500 — Interaction Research Guide
- BPC-157 vs TB-500 — Research Comparison
Supporting Research
Preclinical Onlyanimal/in vitro only — no human efficacy RCTs
Evidence note: No human clinical trials of BPC-157 have been completed. All evidence below is preclinical (animal and cell studies). Claims about efficacy in humans cannot be made from this data.
BPC-157 has been extensively studied in preclinical animal and cell models for tissue repair, angiogenesis, and gastrointestinal protection. All efficacy evidence is from animal (predominantly rat) and in-vitro studies. No completed human clinical trials have established efficacy for any indication.
References
- Seiwerth S, et al.[PRECLINICAL — animal/in vitro]Tissue-healing effects across GI tract, tendon, muscle, etc. in animal models.
- Chang CH, Tsai WC, et al.[PRECLINICAL — rat + in vitro]Tendon fibroblast outgrowth, survival and migration under stress.
Research Databases
PubMedNCBIScienceDirect
Ready to Source BPC-157?
Purgo Labs offers BPC-157 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.